What Is Tesamorelin?
Last reviewed:
Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH). Researchers use it to study GHRH-receptor signalling, endogenous growth-hormone pulsatility and downstream insulin-like growth factor 1 (IGF-1) responses. Lazarus Labs supplies Tesamorelin only as a laboratory reference material.
How is Tesamorelin classified and what is its structure?
Tesamorelin is a synthetic peptide analogue of the 44-amino-acid human GHRH sequence. Its N-terminal modification was developed to improve stability while retaining activity at the GHRH receptor.
Classification describes molecular identity and the receptor system used in research. It does not establish a use, safety profile or expected outcome outside a controlled study.
How is Tesamorelin’s mechanism studied in research?
GHRH-receptor activation is studied for its role in signalling within pituitary somatotroph cells. Controlled studies have measured downstream changes in pulsatile growth-hormone release and IGF-1, together with metabolic and body-composition endpoints defined by each protocol.
Those measurements are study-specific. They should not be extrapolated into a general claim about efficacy, safety or suitability for an individual.
What kind of research has been published on Tesamorelin?
A small controlled study measured endogenous growth-hormone pulsatility and insulin sensitivity over two weeks. Separate randomised protocols examined longer-term endocrine, metabolic and cardiovascular endpoints, with each paper defining its own population and controls. The synthesis literature has continued: a 2026 meta-analysis in Obesity Research & Clinical Practice pooled five randomised controlled tesamorelin trials and summarised their reported endpoints and limitations.
The references below identify the populations, duration, endpoints and limitations of those studies. Lazarus Labs does not convert their findings into therapeutic or performance claims.
What compounds is Tesamorelin studied alongside?
In the published literature, Tesamorelin is grouped with the other GHRH-family analogues — sermorelin and CJC-1295 — and reviewed in the same framework as receptor-distinct growth-hormone secretagogues such as ipamorelin, which act at the ghrelin (GHS) receptor rather than the GHRH receptor. These groupings describe how the compounds are classified in published research; they do not imply equivalence between compounds or any human-use indication.
How is Tesamorelin supplied, tested and handled?
Lazarus Labs supplies Tesamorelin 10MG as a lyophilised reference material with third-party batch documentation and a Certificate of Analysis (COA). Store cold, dry and protected from light in accordance with your laboratory protocol.
References
- Stanley TL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. Journal of Clinical Endocrinology & Metabolism. PMID: 20943777.
- Makimura H, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. Journal of Clinical Endocrinology & Metabolism. PMID: 23015655.
- Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One. PMID: 28617838.
- Badran AS, et al. Obesity Research & Clinical Practice. 2026. PMID: 41545261.
- Dominikowski A, et al. Frontiers in Endocrinology. 2026. PMID: 42395176.
Primary literature verified against PubMed. Citations are provided for scientific reference and do not imply a human-use indication.
Important
For research use only. Not for human or veterinary consumption. Lazarus Labs supplies Tesamorelin solely as a laboratory reference material and makes no therapeutic, medical or performance claims. Nothing on this page is medical advice.